March 16, 2020 10:24am
In all dose groups for adult patients (age 18 years or older), including the two higher dose groups, of its P1/2 clinical programs with achromatopsia due to mutation in the ACHM CNGB3 or ACHM CNGA3 genes. AGTC continues to enroll pediatric patients at the higher dose groups in both trials.
The share price was up and the down -$0.17
BUY post disruption or give it a day, maybe 2
AGTC most recently reported interim six-month data from the dose escalation cohorts of its ongoing ACHM P1/2 clinical trials in January 2020.
Results from both studies demonstrated encouraging signs of biologic activity as shown by positive changes in light discomfort testing as well as encouraging patient anecdotes describing real-world improvements in visual function.
A favorable safety profile with no dose-limiting inflammatory responses was observed.